ByHeart, Inc.
Nutritionally optimized infant formula with novel composition
Updated · byheart.com
- Sector
- Biotech
- Headquarters
- New York, NY
- Founded
- 2017
- Latest Form D
- $72M, Mar 2025
- Total capital
- $361M
- Grants
- —
- No SBIR or STTR on record
- Sector median 1 award
- Raised
- $361M
- 6 Form D · Mar 2025
- 19 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 1 granted · 11 pending
- 6.0× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓2019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $72,177,578 | |
| Private capital raised | Form D · SEC | $80,046,633 | |
| Private capital raised | Form D · SEC | $29,639,049 | |
| Private capital raised | Form D · SEC | $60,589,470 | |
| Private capital raised | Form D · SEC | $96,885,369 | |
| Private capital raised | Form D · SEC | $22,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1089 | Rattan Life Science Inc. | — | — |
| 1090 | KOI BIOTHERAPEUTICS INC. | — | — |
| 1091 | VIVERE ONCOTHERAPIES, INC. | — | — |
| 1092 | ByHeart, Inc. | — | $361M |
| 1093 | BIOTECERA INC. | — | — |
| 1094 | Sidera Bio | — | — |
| 1095 | ROUND TABLE RESEARCH, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Elizabeth AbramsDirector
- Elias AoukarExecutive Officer
- James BauersmithExecutive Officer
- Arie BelldegrunDirector
- Ron BelldegrunDirector · Executive Officer · Promoter
- Joshua BradleyDirector
- Tommy BurkeDirector
- Mia FuntDirector · Executive Officer · Promoter
Show all 22 people
- Joshua KazamDirector
- Georg Krause-VilmarExecutive Officer
- Devon KuehnExecutive Officer
- Anton LinderumDirector
- Niall MullaneExecutive Officer
- Guy OranimDirector
- Robert PeruzziExecutive Officer
- Amy SchulmanDirector
- Allan SebbagExecutive Officer
- Denice TorresDirector
- Michael TullyDirector
- Saloni VarmaExecutive Officer
- Raphael WallanderDirector
- Hemi ZuckerDirector
Patents
- Fatty Acid Compositionsapplication
- Fatty Acid Compositionsapplication
- Formulations For Nutritional Support In Subjects In Need Thereofapplication
- Formulations for Nutritional Support in Subjects in Need Thereofgranted
- Formulations For Nutritional Support In Subjects In Need Thereofapplication
- Formulations for Nutritional Support in Subjects in Need Thereofapplication
- Formulation Comprising Heat-treated Lactoferrin For Nutritional Support In Subjects In Need Thereofapplication
- Nutritional Supplement Comprising Lactoferrin Protein Complexes In Subjects In Need Thereofapplication
- Nutritional Supplement Comprising Lactoferrin Protein Complexes In Subjects In Need Thereofapplication
- Formulation Comprising Heat-treated Lactoferrin For Nutritional Support In Subjects In Need Thereofapplication
- Fatty Acid Compositionsapplication
- Fatty Acid Compositionsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.